Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
October 2011, Vol 2, No 6
October 2011, Vol 2, No 6
New T-DM1 Reduces Disease Progression by 40% in Advanced Breast Cancer, with Low Toxicity
By
Caroline Helwick
October 2011, Vol 2, No 6
Stockholm, Sweden—Trastuzumab emtansine (T-DM1), a novel monoclonal antibody–guided therapy for HER2-positive metastatic breast cancer, achieved almost a 40% reduction in the risk of disease progression compared with standard treatment with trastuzumab (Herceptin) and docetaxel (Taxotere), investigators reported at the 2011 European Multidisciplinary Cancer Congress.
Read Article
Everolimus-Exemestane Combination Prolongs Remission by 4 Months in Metastatic Breast Cancer
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—The use of everolimus (Afinitor) together with the aromatase inhibitor exemestane (Aromasin) more than halved the risk for disease progression in patients with advanced breast cancer, adding an average of 4 disease-free months, investigators reported at the 2011 European Society for Medical Oncology European Multidisciplinary Cancer Congress.
Read Article
Positive Data Continue to Accrue for Crizotinib in ALK-Positive NSCLC
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Read Article
Value of Bevacizumab in Ovarian Cancer Got a Boost in a New Analysis
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—The indefinite use of bevacizumab (Avastin) in patients with re lapsed ovarian cancer got another boost at the 2011 European Multi disciplinary Cancer Congress, with a subanalysis of the phase 3 OCEANS trial showing consistent benefit across subgroups.
Read Article
Pemetrexed Plus Bevacizumab Maintenance Keeps NSCLC at Bay Longer
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—Two expensive drugs may be better than 1 for maintenance treatment of advanced non– small-cell lung cancer (NSCLC), according to a study at the 2011 European Multidisciplinary Cancer Congress.
Read Article
New Bone-Targeting Compound Improves Survival in Metastatic Prostate Cancer
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—An investigational alpha-pharmaceutical not only prevented skeletal-related events (SREs) in patients with prostate cancer with bone metastases in a phase 3 study presented at the 2011 European Multidisciplinary Cancer Congress, but it also improved overall survival.
Read Article
FDA Accelerates Approval of Crizotinib for NSCLC
FDA Approvals, News & Updates
October 2011, Vol 2, No 6
Read Article
Brentuximab Indicated for 2 Types of Lymphomas
FDA Approvals, News & Updates
October 2011, Vol 2, No 6
The FDA expedited the approval of brentuximab vedotin (Adcetris, Seattle Genetics) for the treatment of Hodgkin lymphoma, as well as for systemic anaplastic large-cell lymphoma (ALCL), a rare non-Hodgkin lymphoma that may manifest in several parts of the body, including the lymph nodes, skin, bones, soft tissue, lungs, and liver.
Read Article
Companion Diagnostic for BRAF V600E Mutation
FDA Approvals, News & Updates
October 2011, Vol 2, No 6
Read Article
Vemurafenib Joins Ipilimumab for Treating Metastatic Melanoma
FDA Approvals, News & Updates
October 2011, Vol 2, No 6
The US Food and Drug Administration (FDA) approved the targeted therapy vemurafenib tablets (Zelboraf, Hoffmann-La Roche) for the treatment of patients with unresectable or metastatic mela noma with the BRAF V600E gene mutation.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma